J3372 NDC Crosswalk, Billing Units, ASP Payment & Medicare Reimbursement

📋 J3372 summary

J3372 is a HCPCS Level II J-code used to bill vancomycin hcl (xellia) not therapeutically equivalent to j3370, 500 mg. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J3372: Vancomycin Hcl(J3372)

Code J3372 NDC-Crosswalk 3 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ3372

DescriptorInjection, vancomycin hcl (xellia) not therapeutically equivalent to j3370, 500 mg

Billing unitNot available in current dataset

Payment limit / unit Not available in current dataset

Mapped NDCs3

Data periodNot available in current dataset

Last updatedSource date not available

💊 About Vancomycin DRUG GUIDE

How it is used depends on the product and the route (IV or by mouth).Intravenous (IV) vancomycin treats septicemia (bloodstream infection), infective endocarditis (heart valve infection), skin and skin structure infections, bone infections, and lower respiratory tract infections.

Tyzavan is an IV injection with these same uses.

Oral vancomycin (capsules such as Vancocin, and oral solution) treats Clostridioides difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains.IV vancomycin is not approved for C.

difficile diarrhea, and oral vancomycin does not work for other types of infection.

Read the full Vancomycin drug guide →

Clinical overview from our editorial drug guide for Vancomycin. For billing reference, see the sections above.

🧾 Billing & reimbursement HCPCS · CMS

Medicare payment limit / unit

—

Est. ASP / unit

—

Est. after 2% sequester

—

HCPCS dosage

—

The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly).

Full HCPCS code details (official CMS record)

Long descriptionInjection, vancomycin hcl (xellia) not therapeutically equivalent to j3370, 500 mg

CoverageD — Special coverage instructions apply

Pricing indicator51 — Drug — priced under the ASP methodology

Type of service1 — Medical care

BETOS-2O1E

ASC payment groupYY

Action codeP — Payment change

Effective date2024-01-01

Date added2023-01-01

Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J3372 = 1 unit. Enter a regimen to convert dose → billing units and project a full course.

Dose per administration (unit) Frequency — every days Number of doses NDC / package billed (optional)

Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J3372 CROSSWALKED NDCs

3 NDCs map to J3372. Bill units = how many HCPCS units one package represents.

NDC (11-digit)	Drug	Labeler	Package	Strength	Bill units	NADAC / unit	Status	Source
70594-0056-03	Vancomycin 750 mg/150mL INJECTION, SOLUTION	Xellia	12 BAG in 1 CARTON (70594-056-03) / 150 m...	750 mg/150mL	0.01	—	● Active	PDAC
70594-0057-02	Vancomycin 1.25 g/250mL INJECTION, SOLUTION	Xellia	6 BAG in 1 CARTON (70594-057-02) / 250 mL...	1.25 g/250mL	0.01	—	● Active	PDAC
70594-0058-02	Vancomycin 1.75 g/350mL INJECTION, SOLUTION	Xellia	6 BAG in 1 CARTON (70594-058-02) / 350 mL...	1.75 g/350mL	0.01	—	● Active	PDAC

NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

⚠️ Don't confuse J3372 with… RELATED CODES

Adjacent HCPCS codes that share an ingredient or formulation with J3372. Billing units and payment limits differ — confirm the exact code, strength and form before billing.

Code	Descriptor	Billing unit	Payment limit / unit	How it differs from J3372
J3370	Vancomycin hcl injection	—	—	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J3373	VANCOMYCIN*	10 MG	$0.033	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J3375	VANCOMYCIN*	10 MG	$0.142	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J3374	VANCOMYCIN HCL	10 MG	$0.097	Related ingredient or formulation — confirm strength, form and billing unit before substituting.
J3371	Inj, vancomycin hcl (mylan)	—	—	Related ingredient or formulation — confirm strength, form and billing unit before substituting.

Related codes matched on shared ingredient (CMS Medicare Part B Spending feed). Billing units and payment limits from the CMS ASP Pricing File. Always verify the precise HCPCS code for the product and strength administered.

📊 Medicare utilization & spend CMS · PART B · 2025 (Q1-Q4)

Total Part B spend

$668.22

Claims

18

Beneficiaries

13

Spend / beneficiary

$51.40

Spend / claim

$37.12

Where J3372 ranks among Part B drugs · 2025 (Q1-Q4) · neighbors ±5

Total spending — #890 of 918

#885 BENTYL* J0500 $995.41 #886 GAMMAGRAFT** Q4111 $870.09 #887 METRO IV* J1836 $865.37 #888 CEFUROXIME SODIUM J0697 $741.16 #889 DAPTOMYCIN(J0877) J0877 $700.51 #890 VANCOMYCIN HCL(J3372... J3372 $668.22 #891 PROGESTERONE J2675 $639.25 #892 VASOPRESSIN* J2598 $589.66 #893 NALOXONE HCL(J2310) J2310 $550.85 #894 PARICALCITOL* J2501 $545.05 #895 ARIXTRA* J1652 $502.49

Total claims — #897 of 918

#892 ETHAMOLIN J1430 20 #893 BEIZRAY-ALBUMIN* J9174 20 #894 ACESSO AC, PER SQ CM... Q4312 20 #895 INJ, EPINEPHRINE (BE... J0173 18 #896 DECITABINE J0893 18 #897 VANCOMYCIN HCL(J3372... J3372 18 #898 CEFEPIME-DEXTROSE J0703 17 #899 OCTREOTIDE ACETATE* J2354 17 #900 VANCOMYCIN HCL(J3371... J3371 17 #901 DAUNORUBICIN HCL J9150 17 #902 SURGRAFT FT PER SQ C... Q4268 17

Full breakdown by period (1)

Period	Total spend	Beneficiaries	Claims	$/beneficiary	$/claim
2025 (Q1-Q4)	$668.22	13	18	$51.40	$37.12

Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.

Allowed charges

$167.69

Medicare paid

$146.43

Submitted services

421

Denial rate

93.8%

Allowed / service

$6.45

Submitted charges

$10.2K

Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where J3372 is utilized

⏳

The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.

📊 What bills under J3372

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient

Vancomycin 3

NDC products by labeler

Xellia Pharmaceuticals USA LLC 3

Related NDC directory pages

🧪 All Vancomycin NDCsIngredient 🏭 All Xellia labeler NDCsLabeler 70594 📚 All Glycopeptide Antibacterial NDCsDrug class

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.

HCPCS code & descriptor

CMS HCPCS Level II code file

Loaded

Payment limit & billing unit

CMS Medicare Part B ASP Pricing File (quarterly)

Not available

NDC ↔ HCPCS crosswalk

CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)

3 NDCs mapped

NADAC acquisition cost

CMS National Average Drug Acquisition Cost (weekly)

Not available for mapped NDCs

Utilization & spend

CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners

Latest data year 2025

Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J3372 billing FAQ

What is HCPCS code J3372?

J3372 is a HCPCS Level II J-code used to bill Injection, vancomycin hcl (xellia) not therapeutically equivalent to j3370, 500 mg under Medicare Part B and most medical (not pharmacy) benefits.

Which NDCs bill under J3372?

3 NDCs currently map to J3372 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.

Does a crosswalk mean J3372 is covered?

No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.

J3372 – Injection, vancomycin hcl (xellia) not therapeutically equivalent to j33 · NDC Crosswalk & Billing Units